Results 41 to 50 of about 5,005,064 (282)

Discrepancies in symptom concerns and burden from the perspectives of parkinson's disease patients, caregivers, and physicians

Frontiers in Neurology
BackgroundDiscrepancies in symptom concerns and the perceived burden among individuals with Parkinson's disease (PD), their caregivers, and their physicians can hinder effective care.ObjectivesWe investigated differences in symptom recognition and ...
Shohei Okusa, Shohei Okusa, Shohei Okusa, Toshiki Tezuka, Toshiki Tezuka, Toshiki Tezuka, Tomonori Nukariya, Tomonori Nukariya, Tomonori Nukariya, Yoshihiro Nihei, Yoshihiro Nihei, Yoshihiro Nihei, Jin Nakahara, Jin Nakahara, Jin Nakahara, Morinobu Seki, Morinobu Seki, Morinobu Seki   +17 more
doaj   +1 more source

Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease

Neurobiology of Disease, 2011
Cell adhesion molecules might play an important role in the inflammatory mechanisms associated with neurodegeneration. We have previously observed, in rats, that subcutaneous injection of complete Freund's adjuvant (CFA), a pro-inflammatory agent that ...
Marie-Therese Armentero, Giovanna Levandis, Eleonora Bazzini, Silvia Cerri, Cristina Ghezzi, Fabio Blandini   +5 more
doaj   +1 more source

Progress Notes : a report from the Parkinson's Disease Center at Boston University Medical Center [PDF]

, 1989
News and updates from the Boston University Medical Center, Parkinson's Disease ...
Parkinson's Disease Center at Boston University Medical Center
core   +1 more source

Treatment of dystonia and tics

Clinical Parkinsonism & Related Disorders, 2020
Treatment of dystonia and tics continues to evolve. In dystonia, while oral agents such as benzodiazepines, baclofen and anticholinergics remain in use, botulinum toxin (BoNT) continues to be regarded as the treatment of choice for focal and segmental ...
Steven Bellows, Joseph Jankovic
doaj   +1 more source

Musculoskeletal Pain in Parkinson's Disease

Frontiers in Neurology, 2022
BackgroundMusculoskeletal pain is commonly experienced in patients with Parkinson's disease (PD). Few studies have investigated the clinical characteristics and risk factors associated with musculoskeletal pain.ObjectivesTo investigate the distribution ...
Jun Li, Jun Li, Ben-Fan Zhu, Zhu-Qin Gu, Zhu-Qin Gu, Hui Zhang, Hui Zhang, Shan-Shan Mei, Shan-Shan Mei, Shao-Zhen Ji, Shao-Zhen Ji, Shu-Ying Liu, Shu-Ying Liu, Chao Han, Chao Han, Huai-Zhen Chen, Piu Chan, Piu Chan, Piu Chan, Piu Chan, Piu Chan   +20 more
doaj   +1 more source

Dopaminergic medication boosts action-effect binding in Parkinson's disease [PDF]

, 2010
Parkinson's disease (PD) is a neurodegenerative disorder affecting voluntary motor control. However, little is known about the experience of voluntary action in PD patients.
Bhatia, Kailash P., Moore, James W., Schneider, Susanne A., Schwingenschuh, Petra, Haggard, Patrick, Moretto, Giovanna   +5 more
core   +1 more source

Progress Notes : a report from the Parkinson's Disease Center at Boston University Medical Center [PDF]

, 1996
News and updates from the Boston University Medical Center Parkinson's Disease ...
Parkinson's Disease Center at Boston University Medical Center
core   +1 more source

Amantadine-based combination therapy of Parkinson’s disease to prevent fluctuation and dyskinesia – experiences from a Parkinson outpatient clinic

Frontiers in Aging Neuroscience
BackgroundThe standard therapy of Parkinson’s disease consists in supplementing the depleted dopamine with oral levodopa. The disadvantages of the levodopa monotherapy – comparable to other dopaminergic substances – are the dose-dependent development of ...
Christian Oehlwein, Lucas Netzel, Lucas Netzel, Katrin Mittmann, Marita Oehlwein, Walter J. Schulz-Schaeffer   +5 more
doaj   +1 more source

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment

Clinical Parkinsonism & Related Disorders, 2023
Dopamine agonists (DAs) have demonstrated efficacy for the treatment of Parkinson’s disease (PD) but are limited by adverse effects (AEs). DAs can vary considerably in their receptor subtype selectivity and affinity, chemical composition, receptor ...
Stuart H. Isaacson, Robert A. Hauser, Rajesh Pahwa, David Gray, Sridhar Duvvuri   +4 more
doaj   +1 more source

The frequency and validity of self-reported diagnosis of Parkinson's Disease in the UK elderly: MRC CFAS cohort [PDF]

, 2006
Background: Estimates of the incidence and prevalence of chronic diseases can be made using established cohort studies but these estimates may have lower reliability if based purely on self-reported diagnosis.Methods: The MRC Cognitive Function & Ageing ...
MRC CFAS, The, Matthews, FE, Foltynie, Thomas, Brayne, C, Carol Brayne, Thomas Foltynie, Ishihara, Lianna, null null, Brayne, Carol, Lianna Ishihara, Foltynie, T, Ishihara, L, Matthews, Fiona E., Fiona E Matthews   +13 more
core   +2 more sources